Vol 94, No 4 (2023)
Research paper
Published online: 2022-05-12

open access

Page views 2498
Article views/downloads 658
Get Citation

Connect on Social Media

Connect on Social Media

Hematological and biochemical markers in determining the diagnosis and stage prediction of endometrial cancer

Aleksandra Nadezda Petric12, Radomir Živadinović12, Dejan Mitić12, Marko Stanojević2, Aleksandar Živadinović2, Ivana Kostić3
Pubmed: 35894501
Ginekol Pol 2023;94(4):283-290.

Abstract

Objectives: To establish whether there is a statistically significant difference in hematological and biochemical parameters between the patients with premalignant changes of the uterine mucosa and those with malignant changes. The aim is to establish whether hematological and biochemical parameters may be useful in predicting the stages of endometrial malignancy and in differentiating premalignant and malignant endometrial changes.
Material and methods: A retrospective study included 100 patients (70 with endometrial carcinoma diagnosis and 30 with atypical hyperplasia). We compared hematological and biochemical parameters in both groups.
Results: CRP, granulocytes, platelets, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) are statistically significantly higher in patients with malignant changes. Lymphocyte count is statistically significantly lower in patients with malignant changes. Platelet count is statistically significantly lower in patients with stages I and II in comparison to patients with higher disease stage. NLR and PLR have good discriminatory power for carcinoma presence. Patients with advanced changes have statistically significantly higher CRP values, higher granulocyte and platelet count, as well as higher values of NLR and PLR, and statistically significantly lower values of lymphocytes and MPV in comparison to
benign changes.
Conclusions: There is a possibility of using hematological and biochemical parameters in the assessment of endometrial changes as well as in the prediction of stages, in confirmed malignant changes of the endometrium.

Article available in PDF format

View PDF Download PDF file

References

  1. Felix AS, Yang HP, Bell DW, et al. Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. Adv Exp Med Biol. 2017; 943: 3–46.
  2. Gu B, Shang X, Yan M, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 2021; 161(2): 573–580.
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
  4. Weiderpass E, Antoine J, Bray FI, et al. Trends in corpus uteri cancer mortality in member states of the European Union. Eur J Cancer. 2014; 50(9): 1675–1684.
  5. Djordjević B, Stanojević Z. [Endometrial carcinoma and precursor lesions]. Srp Arh Celok Lek. 2007; 135(3-4): 230–234.
  6. Inoue H, Saegusa M. Is endometrial carcinoma in situ a precursor lesion of endometrial carcinoma? Kitasato Med J. 2018; 48: 1–8.
  7. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985; 56(2): 403–412, doi: 10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x.
  8. Scioscia M, Noventa M, Laganà AS. Abnormal uterine bleeding and the risk of endometrial cancer: can subendometrial vascular ultrasound be of help to discriminate cancer from adenomyosis? Am J Obstet Gynecol. 2020; 223(4): 605–606.
  9. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016; 93(6): 468–474.
  10. Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017; 124(3): 404–411.
  11. Baral R, Pudasaini S. Histopathological pattern of endometrial samples in abnormal uterine bleeding. Journal of Pathology of Nepal. 1970; 1(1): 13–16.
  12. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018; 178(9): 1210–1222.
  13. Chen M, Jin Y, Li Y, et al. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016; 132(1): 34–38.
  14. Gressel GM, Parkash V, Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015; 131(3): 234–239.
  15. Rodolakis A, Biliatis I, Morice P, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer. 2015; 25(7): 1258–1265.
  16. Ohyagi-Hara C, Sawada K, Aki I, et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015; 291(1): 151–157.
  17. WHO Classification of Tumours Editorial Board. Female Genital Tumours: WHO Classification of Tumours, 5th ed. IARC, Lyon 2020.
  18. Yayla Abide C, Bostanci Ergen E, Cogendez E, et al. Evaluation of complete blood count parameters to predict endometrial cancer. J Clin Lab Anal. 2018; 32(6): e22438.
  19. Karateke A, Kaplanoglu M, Baloglu A. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer. Asian Pac J Cancer Prev. 2015; 16(12): 4905–4908.
  20. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018; 11(1): 125.
  21. Huong PT, Nguyen LT, Nguyen XB, et al. The Role of Platelets in the Tumor-Microenvironment and the Drug Resistance of Cancer Cells. Cancers (Basel). 2019; 11(2).
  22. Korniluk A, Koper-Lenkiewicz OM, Kamińska J, et al. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019; 2019: 9213074.
  23. Kurtoglu E, Kokcu A, Celik H, et al. Platelet Indices May be Useful in Discrimination of Benign and Malign Endometrial Lesions, and Early and Advanced Stage Endometrial Cancer. Asian Pac J Cancer Prev. 2015; 16(13): 5397–5400.
  24. Song J, Lai X, Zhang Y, et al. Preoperative platelet morphology parameters as prognostic predictors for endometrial malignant carcinoma stage and progesterone receptor. Medicine (Baltimore). 2019; 98(47): e17818.
  25. Oge T, Yalcin OT, Ozalp SS, et al. Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstet Gynaecol Res. 2015; 41(3): 445–448.
  26. Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014; 124(2): 184–187.
  27. Sharma D, Singh G. Thrombocytosis in gynecological cancers. J Cancer Res Ther. 2017; 13(2): 193–197.
  28. Haruma T, Nakamura K, Nishida T, et al. Pre-treatment neutrophil to lymphocyte ratio is a predictor of prognosis in endometrial cancer. Anticancer Res. 2015; 35(1): 337–343.
  29. Suh DH, Kim HS, Chung HH, et al. Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 2012; 162(2): 206–210.
  30. Wang D, Yang JX, Cao DY, et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther. 2013; 6: 211–216.
  31. Pergialiotis V, Oikonomou M, Damaskou V, et al. Platelet to lymphocyte and neutrophil to lymphocyte ratio as predictive indices of endometrial carcinoma: Findings from a retrospective series of patients and meta-analysis. J Gynecol Obstet Hum Reprod. 2018; 47(10): 511–516.
  32. Temur I, Kucukgoz Gulec U, Paydas S, et al. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2018; 226: 25–29.
  33. Ural ÜM, Şehitoğlu İ, Tekin YB, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015; 41(3): 445–448.
  34. Dong Y, Cheng Y, Wang J. The Ratio of Neutrophil to Lymphocyte is a Predictor in Endometrial Cancer. Open Life Sci. 2019; 14: 110–118.
  35. Ni L, Tao J, Xu J, et al. Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020; 301(1): 251–261.
  36. Friedenreich CM, Langley AR, Speidel TP, et al. Case-control study of inflammatory markers and the risk of endometrial cancer. Eur J Cancer Prev. 2013; 22(4): 374–379.
  37. Terlikowska KM, Dobrzycka B, Terlikowski R, et al. Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer. BMC Cancer. 2020; 20(1): 921.